Search alternatives:
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
ic cases » 19 cases (Expand Search), _ cases (Expand Search), 3 cases (Expand Search)
ad cases » all cases (Expand Search), 19 cases (Expand Search), _ cases (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), i large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), i large (Expand Search)
Showing 141 - 160 results of 7,759 for search '(((( b large decrease ) OR ( c large decrease ))) OR ( ((ic cases) OR (ad cases)) increased ))*', query time: 0.49s Refine Results
  1. 141
    Example images from the (a) Cytoplasm dataset and (b) LIVECell dataset used for training and example images from each of our evaluation datasets, (c) PBL-HEK and (d) PBL-N2a.

    Example images from the (a) Cytoplasm dataset and (b) LIVECell dataset used for training and example images from each of our evaluation datasets, (c) PBL-HEK and (d) PBL-N2a. by Alexandra Dunnum VandeLoo (22209218)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 142
    The HMR C-terminus is required for HMR localization in proximity to centromeres and HP1a-bound chromatin.

    The HMR C-terminus is required for HMR localization in proximity to centromeres and HP1a-bound chromatin. by Andrea Lukacs (3752956)

    Published 2021
    Save to List
    Saved in:
  3. 143
    Smart Predict: adding partner-suggested vocabulary to increase efficiency in a dual tablet AAC typing application

    Smart Predict: adding partner-suggested vocabulary to increase efficiency in a dual tablet AAC typing application by Melanie Fried-Oken (5128913)

    Published 2024
    Save to List
    Saved in:
  4. 144
    The HMR C-terminus is required for HMR physiological function in <i>D</i>. <i>melanogaster</i>.

    The HMR C-terminus is required for HMR physiological function in <i>D</i>. <i>melanogaster</i>. by Andrea Lukacs (3752956)

    Published 2021
    Save to List
    Saved in:
  5. 145
    HbA1c by BMI for new and previous diabetes diagnoses at start of TB treatment.

    HbA1c by BMI for new and previous diabetes diagnoses at start of TB treatment. by Sharon E. Cox (7243847)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  6. 146
    Differential expression analysis of nuclear transcripts after siAPOBEC3A depletion reveals induction of TP53 targets and decreases in cell cycle and cell growth regulator transcripts.

    Differential expression analysis of nuclear transcripts after siAPOBEC3A depletion reveals induction of TP53 targets and decreases in cell cycle and cell growth regulator transcrip... by Mason A. McCool (11889842)

    Published 2024
    Save to List
    Saved in:
  7. 147
    Incidence rate ratio (IRR) of outpatient visits between IC/BPS and non-IC/BPS individuals categorized by 3 age groups.

    Incidence rate ratio (IRR) of outpatient visits between IC/BPS and non-IC/BPS individuals categorized by 3 age groups. by Kun-Lin Hsieh (11401919)

    Published 2021
    Save to List
    Saved in:
  8. 148
    (a) A single Phase Contrast image of HEK cells from our PBL-HEK dataset, (b) annotated manually by an expert, (c) automatically annotated by Meta’s SAM-huge model, and (d) automatically annotated by our SAMCell model.

    (a) A single Phase Contrast image of HEK cells from our PBL-HEK dataset, (b) annotated manually by an expert, (c) automatically annotated by Meta’s SAM-huge model, and (d) automati... by Alexandra Dunnum VandeLoo (22209218)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 149
    The rate the bias decreases with sample duration is higher for cells with higher activity levels.

    The rate the bias decreases with sample duration is higher for cells with higher activity levels. by Liron Sheintuch (12078310)

    Published 2022
    Save to List
    Saved in:
  10. 150
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 151
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 152
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 153
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 154
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 155
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 156
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 157
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 158
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 159
    Ribosomal subunit pathways are decreased in <i>Resf1</i> knockdown cells.

    Ribosomal subunit pathways are decreased in <i>Resf1</i> knockdown cells. by Megan R. Majocha (18529925)

    Published 2024
    “…<p>(A) GO Pathway analysis snapshots of various ribosomal subunit pathways that are decreased in 6DT1 <i>Resf1</i> KD cells. (B) The GO Cytosolic Ribosome pathway had many (C) small and large ribosomal proteins decreased in <i>Resf1</i> KD cells. …”
    Save to List
    Saved in:
  20. 160
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: